Thrombolytic studies of Streptokinase from Streptococcus pyogenes - Aher, Vaibhav
19,99 €
inkl. MwSt.

Versandfertig in 6-10 Tagen
  • Broschiertes Buch

Life would not long remain possible in the absence of microbes. Many of common problems in clinical practice today relate to thrombosis. Streptokinase is the first thrombolytic drug to be described and was introduced for myocardial infarction more than 40 years ago. It is now the leading thrombolytic agent and is included in the World Health Organization (WHO) model list of essential medicine. A failure of hemostasis and consequent development of blood clots in the circulatory system can produce severe consequences such as acute myocardial infarction and ischemic stroke, both leads to cause of…mehr

Andere Kunden interessierten sich auch für
Produktbeschreibung
Life would not long remain possible in the absence of microbes. Many of common problems in clinical practice today relate to thrombosis. Streptokinase is the first thrombolytic drug to be described and was introduced for myocardial infarction more than 40 years ago. It is now the leading thrombolytic agent and is included in the World Health Organization (WHO) model list of essential medicine. A failure of hemostasis and consequent development of blood clots in the circulatory system can produce severe consequences such as acute myocardial infarction and ischemic stroke, both leads to cause of death. Pathological development of blood clots requires clinical intervention with fibrinolytic agents such as tissue plasminogen activator and streptokinase. This book deals with streptokinase as a clinically important and plasminogen activator by the studies.
Autorenporträt
Dr. Vaibhav Dagaji Aher completed bachelors in Pharmacy, Masters in Pharmaceutical Biotechnology, PhD in Pharmaceutical Sciences and has Postdoctoral research experience from India and USA in the field of immunology, toxicology, radiation health.